SD:專項披露公告
04/25 06:11 (美東)
武田製藥:美國FDA批准武田ENTYVIO®(vedolizumab)皮下注射用於中度至重度活動性克羅恩病的維持治療
04/19 06:15 (美東)
TAKEDA PHARMACEUTICAL CO LTD | 6-K:外國發行人報告
04/15 06:33 (美東)
TAKEDA PHARMACEUTICAL CO LTD | SC 13D/A:超過5%持股股東披露文件(修正)-Takeda Pharmaceutical Company Limited(4.8%)
04/10 06:12 (美東)
TAKEDA PHARMACEUTICAL CO LTD | SC 13D/A:超過5%持股股東披露文件(修正)-Takeda Pharmaceutical Company Limited(5.4%)
04/01 06:21 (美東)
TAKEDA PHARMACEUTICAL CO LTD | 6-K:外國發行人報告
03/27 06:38 (美東)
TAKEDA PHARMACEUTICAL CO LTD | 6-K:外國發行人報告
02/09 06:09 (美東)
TAKEDA PHARMACEUTICAL CO LTD | SC 13G/A:超過5%持股股東披露文件(修正)-BlackRock, Inc.(7.7%)
02/06 09:43 (美東)
TAKEDA PHARMACEUTICAL CO LTD | SC 13G/A:超過5%持股股東披露文件(修正)-Sumitomo Mitsui Trust Holdings, Inc.(5.5%)
02/05 06:27 (美東)
TAKEDA PHARMACEUTICAL CO LTD | 6-K:外國發行人報告(業績相關)
02/02 06:20 (美東)
TAKEDA PHARMACEUTICAL CO LTD | 6-K:外國發行人報告
02/01 06:21 (美東)
TAKEDA PHARMACEUTICAL CO LTD | 6-K:外國發行人報告(業績相關)
02/01 06:12 (美東)
TAKEDA PHARMACEUTICAL CO LTD | 4:持股變動聲明-股東 TAKEDA PHARMACEUTICAL CO LTD
01/25 06:14 (美東)
TAKEDA PHARMACEUTICAL CO LTD | SC 13D/A:超過5%持股股東披露文件(修正)-Takeda Pharmaceutical Company Limited(6.6%)
01/25 06:14 (美東)
TAKEDA PHARMACEUTICAL CO LTD | SC 13G:超過5%持股股東披露文件-Takeda Pharmaceutical Company Limited(5.2%),Takeda Ventures, Inc(5.2%)
01/19 00:00 (美東)
TAKEDA PHARMACEUTICAL CO LTD | 6-K:外國發行人報告
01/16 00:00 (美東)
TAKEDA PHARMACEUTICAL CO LTD | 6-K:外國發行人報告(業績相關)
2023/12/14 06:01 (美東)
TAKEDA PHARMACEUTICAL CO LTD | 6-K:外國發行人報告(業績相關)
2023/11/30 06:01 (美東)
TAKEDA PHARMACEUTICAL CO LTD | 6-K:外國發行人報告
2023/11/13 06:05 (美東)
TAKEDA PHARMACEUTICAL CO LTD | 6-K:外國發行人報告(業績相關)
2023/10/30 06:02 (美東)
暫無數據
暫無數據